Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Das neue Gebäude ist Teil einer Investition in Höhe von CHF 1,4 Milliarden in den Standort und unterstreicht das Engagement von Roche in der Schweiz und für den Life Sciences Cluster Basel.Das...
-
The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences clusterThe Institute of Human Biology (IHB) enables scientists...
-
With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. The new computational...
-
Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt39....
-
Adoption de toutes les propositions du Conseil d’administration Réélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil...
-
Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed39th...
-
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus...
-
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the...
-
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerabilityAt the maximally effective dose, there...
-
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with...